Supplements · Metabolic & Cardiometabolic
garlic decreases LDL cholesterol
In plain terms: Does garlic lower cholesterol?
Leans support Supplements 🔬 Includes disconfirming
Part of: 🧪 Garlic
RefutedContestedStrong support
consensus score 0.21
It's genuinely mixed. Garlic tends to nudge total cholesterol down a little, but its effect on LDL (the number that matters most) is inconsistent — and the most carefully controlled trial found no effect at all. Don't rely on it as a cholesterol treatment.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
10 support 4 contradict 0 tested null 0 mixed · 14 sources, 14 independent groups · 2 superseded — pooled inside a review, counted once
What the evidence shows
Whether garlic lowers LDL cholesterol is contested. Several meta-analyses report modest reductions, but the most rigorous RCT (Gardner 2007, raw garlic + two supplements) found NO effect, and multiple analyses find total cholesterol drops while LDL specifically does not. TC and LDL do not move together here.
The evidence (17)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Gardner CD, Lawson LD, Block E, Chatterjee LM, Kiazand A, Balise RR, Kraemer HC 2007 · Arch Intern Med | RCT | contradicts | high | 6-mo RCT (n=192, moderate hypercholesterolemia): raw garlic + powdered + aged-extract supplements - NO significant effect on LDL or any lipid vs placebo. The most rigorous garlic-lipid trial. ↩ SUPERSEDED — pooled in the review above, counted once |
| Hesari NG, Sadatmahalleh SJ, Mohebbi P, Nasiri M, Khosravi A 2025 · J Health Popul Nutr | RCT | supports | moderate | Double-blind placebo RCT, 97 Iranian women with PCOS + metabolic syndrome, garlic 500 mg tablet (2-3 mg allicin) twice daily for 8 weeks. Table 1: LDL-C 90.04 -> 83.48 mg/dL (baseline-adjusted mean) vs placebo 89.27 -> 91.89, F=19.484, P<0.001; TC also fell (185.66 -> 163.32 vs 177.37, P<0.001) while HDL-C did not move ('Although HDL-C level increased following garlic consumption, the difference between the groups was not statistically significant.'). Two caveats the abstract-based extract omitted: baseline LDL-C was already normal (~90 mg/dL), so this is not a hyperlipidemic population, and the abstract's 14.2% reduction is larger than the 7.3% implied by Table 1's adjusted means. Diet and physical activity were not monitored over the 8 weeks, during which the garlic arm also lost 4.4 kg. |
| Kheirmandparizi M, Keshavarz P, Nowrouzi-Sohrabi P, Hosseini-Bensenjan M, Rezaei S, Kashani SMA, Zeidi N, Tabrizi R, Alkamel A 2021 · Int J Clin Pract | meta-analysis | contradicts | moderate | Meta 6 RCTs in coronary-artery-disease patients: TC dropped (-16.3 mg/dL) but LDL NOT significant (-3.65, p=0.46) - TC and LDL diverge. |
| Zhao X, Cheng T, Xia H, Yang Y, Wang S 2024 · Nutrients | meta-analysis | supports | low | Meta of 22 RCTs/29 trials: LDL-C -8.20 mg/dL (95% CI -15.58, -0.81; p=0.03) from 18 studies/21 effect sizes at I2=93.2%, with Egger's test p=0.001 (publication bias present for LDL). TC -14.17 mg/dL (-19.31, -9.03; I2=70.7%, Egger p=0.011) and HDL-C +2.06 mg/dL (1.54, 2.59; I2=0.0%); TG null (-4.88; -11.1, 1.35; p=0.125). The LDL result is subgroup-fragile: not significant for aged garlic extract (p=0.108), 'Other' preparations (p=0.061), hyperlipidemia (-4.58, p=0.527), healthy adults (-1.95, p=0.697) or trials <=8 weeks (p=0.089); it is carried by the T2DM subgroup (-26.11). Pools Gardner 2007, Jung 2014, Sobenin (Acta Diabetol 2008;45:1-6) and Szulinska 2018 among its 22 articles. |
| Fu Z, Lv J, Gao X, Zheng H, Shi S, Xu X, Zhang B, Wu H, Song Q 2023 · BMC Complement Med Ther | meta-analysis | supports | moderate | Meta 19 RCTs (n=999): TC SMD -0.43, LDL SMD -0.44; high heterogeneity, possible publication bias. |
| Li S, Guo W, Lau W, Zhang H, Zhan Z, Wang X, Wang H 2022 · Crit Rev Food Sci Nutr | meta-analysis | supports | moderate | Meta 22 RCTs: TC and LDL lowered, more noticeably at lower dose / longer duration, especially in CVD patients. |
| Tang YY, Lv D 2025 · Scientific reports | in-vitro | supports | low | In-vitro study of alliin (garlic-derived organosulfide) in ox-LDL-injured HUVECs; alliin upregulated LDL-receptor (LDLR) and ApoC while downregulating ApoB, implicated in favorable cholesterol-metabolism pathway modulation. |
| Ahmad P, Shah A, Alvi SS, Chaturvedi CP, Ahmad S, Bin Sheeha B, Puri P, Alothamali OW, Khan MS 2026 · Frontiers in pharmacology | animal | supports | low | Rat model of high-carb/high-fat diet-induced metabolic syndrome; diallyl trisulfide (garlic organosulfur compound) downregulated PCSK9/HMG-CoA reductase and upregulated LDL-receptor expression, corroborated by reduced plasma LDL-C and TC. |
| Isaacsohn JL, Moser M, Stein EA, Dudley K, Davey JA, Liskov E, Black HR 1998 · Arch Intern Med | RCT | contradicts | high | Double-blind placebo-controlled 12-wk multicenter RCT, hypercholesterolaemic patients (garlic n=28, placebo n=22), Kwai garlic powder 900 mg/d: 'no significant difference between changes in the placebo-treated group compared with changes in the garlic-treated patients' for any lipid incl. LDL; authors: 'ineffective in lowering cholesterol levels'. Null on the directional claim -> contradicts. No LDL estimate/CI in abstract; small trial (n=50). |
| Simons LA, Balasubramaniam S, von Konigsmark M, Parfitt A, Simons J, Peters W 1995 · Atherosclerosis | RCT | contradicts | high | Double-blind placebo-controlled randomised crossover (12 wk each arm, 28-day washout), mild-moderate hypercholesterolaemia under dietary supervision, Kwai garlic powder 900 mg/d, 28 analysable: 'Mean LDL cholesterol concentration was 4.64 +/- 0.52 mmol/l on garlic and 4.60 +/- 0.59 mmol/l on placebo'; no significant lipid differences. Null on the directional claim -> contradicts. Also no effect on LDL oxidisability, lathosterol/cholesterol, or lymphocyte LDL-receptor expression. |
| Kannar D, Wattanapenpaiboon N, Savige GS, Wahlqvist ML 2001 · J Am Coll Nutr | RCT | supports | moderate | RCT n=46: enteric-coated garlic TC -4.2%, LDL -6.6% vs placebo (which rose). |
| Liang N, Liu JH, Li Q, He Z, Huang X, Chen ZY 2025 · Phytomedicine : international journal of phytotherapy and phytopharmacology | observational | supports | moderate | Narrative review (Scopus/PubMed search of in vitro, in vivo, RCT studies) concludes garlic reduces plasma TC and LDL-C with concomitant HDL-C increase; notes efficacy requires long supplementation (>2 months) in mild-to-moderate hypercholes |
| Du Y, Zhou H, Zha W 2024 · J Health Popul Nutr | meta-analysis | supports | moderate | Meta 21 RCTs: LDL -0.44 mmol/L (~-17 mg/dL), TC -0.64; garlic oil more effective than powder. |
| Jung ES, Park SH, Choi EK, Ryu BH, Park BH, Kim DS, Kim YG, Chae SW 2014 · Nutrition | RCT | contradicts | moderate | 12-wk RCT aged black garlic (mild hypercholesterolemia): no significant LDL / TC / TG change; only HDL rose. LDL specifically null. ↩ SUPERSEDED — pooled in the review above, counted once |
| Bashiri S, TaghipourSheshdeh F, Foshati S, Askarpour M, Ahmadi A, Babajafari S 2025 · Phytother Res | meta-analysis | supports | high | Meta 19 RCTs: aged garlic lowered LDL -4.41 mg/dL; TC only approached significance (-4.74, borderline). |
| Khoo YS, Aziz Z 2009 · J Clin Pharm Ther | meta-analysis | contradicts | moderate | Meta-analysis of 13 RCTs (n=1056; 11-24 wk; healthy + hypercholesterolaemic): LDL mean difference 0.01 mmol/L (95% CI -0.10 to 0.11), TC -0.04 (95% CI -0.15 to 0.07). A precise null on the directional claim -> contradicts. Authors: 'moderate to high heterogeneity exists among pooled studies, conclusive recommendations cannot be made' -> quality moderate. LDL pool size not separately stated (13 trials is the eligible set). |
| Tang Y, Lv D, Tao Y, Wang J 2025 · Frontiers in cardiovascular medicine | animal | supports | low | Narrative review of garlic-derived organosulfur compounds (OSCs) in atherosclerosis; states preclinical and clinical investigations show OSCs 'significantly reduce plasma cholesterol' via Nrf2/AMPK/PCSK9-LDLR pathways, while flagging bioava |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.